Arax Advisory Partners’s Definium Therapeutics DFTX Stock Holding History

Arax Advisory Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.3K	Buy	793 +327	+70%	+$8.08K	﹤0.01%	3510
2026 Q1	$8.81K	Sell	466 -13	-3%	-$221	﹤0.01%	2511
2025 Q4	$6.41K	Buy	+479	New	+$5.93K	﹤0.01%	2713
2025 Q3	–	Sell	-501	Closed	-$3.25K	–	4050
2025 Q2	$3.25K	Buy	501 +237	+90%	+$1.56K	﹤0.01%	2391
2025 Q1	$1.54K	Sell	264 -12	-4%	-$86	﹤0.01%	2158
2024 Q4	$1.92K	Buy	276 +248	+886%	+$1.71K	﹤0.01%	2021
2024 Q3	$160	Hold	28	–	–	﹤0.01%	2530
2024 Q2	$202	Hold	28	–	–	﹤0.01%	2438
2024 Q1	$264	Hold	28	–	–	﹤0.01%	1267
2023 Q4	$103	Hold	28	–	–	﹤0.01%	1310
2023 Q3	$88	Hold	28	–	–	﹤0.01%	1300
2023 Q2	$100	Hold	28	–	–	﹤0.01%	1250
2023 Q1	$89	Hold	28	–	–	﹤0.01%	1252
2022 Q4	$62	Buy	+28	New	+$78	﹤0.01%	1257
2022 Q1	–	Sell	-29	Closed	-$1K	–	1186
2021 Q4	$1K	Buy	29 +3	+12%	+$96	﹤0.01%	1041
2021 Q3	$1K	Hold	26	–	–	﹤0.01%	921
2021 Q2	$1K	Buy	+26	New	+$1.36K	﹤0.01%	886

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Arax Advisory Partners's DFTX Position: Q2 2026 in Review

Arax Advisory Partners increased its Definium Therapeutics (DFTX) stake by 70% in Q2 2026, buying an estimated $8.08K and bringing the position to 793 shares worth $37.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Arax Advisory Partners first reported a position in DFTX in Q2 2021 and has held it in 17 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Arax Advisory Partners held 793 shares of Definium Therapeutics worth $37.3K as of Q2 2026.
Arax Advisory Partners bought 327 Definium Therapeutics shares in Q2 2026, an estimated $8.08K.
Definium Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3510 holding.
Arax Advisory Partners first reported a position in Definium Therapeutics in Q2 2021 and has held it in 17 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.